Evidence map›Paper›PMID 37164675›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Autoimmune Pulmonary Alveolar Proteinosis That Improved after a COVID-19 Episode.

Atsushi Yanagisawa, Takayuki Takimoto, Ryota Shintani, Takehiko Kobayashi, Masaki Hirose, Toru Arai, Yoshikazu Inoue

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Atsushi YanagisawaDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
Takayuki TakimotoDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
Ryota ShintaniDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
Takehiko KobayashiClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
Masaki HiroseClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
Toru AraiClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
Yoshikazu InoueClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan.
National Kinki Chuo Hospital for Chest Disease · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune pulmonary alveolar proteinosis (APAP) is caused by macrophage dysfunction owing to the presence of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies. A 77-year-old man with APAP was referred to our hospital for whole-lung lavage (WLL) due to oxygenation exacerbation and pulmonary shadows. The patient had had coronavirus disease 2019 (COVID-19) during the APAP evaluation before WLL. About three months after COVID-19 resolved, his oxygenation and shadow reflecting APAP had obviously improved, thus avoiding the need for WLL. We suspected that the improvement in APAP was due to various immunological reactions induced by COVID-19.

Indexed as

Autoimmune DiseasesCOVID-19Pulmonary Alveolar ProteinosisAgedAutoantibodiesHumansLungMaleTreatment OutcomeAutoantibodiescoronavirus disease 2019 (COVID-19)granulocyte-macrophage colony-stimulating factor (GM-CSF)pulmonary alveolar proteinosisviral infection

Identifiers

PMID37164675
PMCPMC10465295
OpenAlexW4376133422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.